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Chronic/~ aeruginosa irway infection is a major cause of morbidity and mortality 
in CF. Aerosol antibiotic delivery to the lungs is an attractive alternative to systemic 
administration. Tobr amycin Inhalation Solution is approved for use in CF patients, 
but has been associated with decreased t obr amycin susceptibility, based on minimal  
inhibitory concentrations (MIC). A I  represents a new therapy specifically 
formulated for aerosol administration via an eFlow ®Electronic Nebulizer. ha a 
randomized, double bl ind trial, CF patients (FEW 1 >40% predicted) received AI  
75 mg (n 37), A I  225 nag (n 37), or placebo (n 31) BID for 14 days. Sputum 
samples were collected on days 0, 7, 14 and 28 for quantitative culture and 
susceptibility testing. At  days 7 and 14, CFU density decreased >1.5 lOgl0 for AI  
75 mg and >2.1 lOgl0 for AI  225 mg (P <0.001). Basel ine/~ aeruginosa MICs0 and 
MIC~0 for AI  were < 1 mad 16 gg/mL for placebo, 2 and 64 pg/mL for AI 75 nag, mad 
<1 and 128 pg/mL for AI  225 mg groups, respectively. At day 14, there was no 
increase ha MIC~0 or MIC~0 with placebo or AI  75 rag, and only a slight increase in 
MIC~0 with AI  225 rag. At day 28, MICs0 retunaed to baseline ha placebo and AI 225 
mg groups, mad a 1 dilution increase was seen in AI  75 nag. MICg0 increased 1
dilution from baseline for placebo and AI 75 mg, but was tmchanged for AI 225 nag. 
AI  appeared to effectively reduce bacterial load and increased resistance was not 
apparent with 14 days treatment with <225 nag AI  BID. AI could provide an 
important option in the management of FA ha CF patients. Further study of the 
safety and efficacy of AI is ongoing. 
2O7 
In Vitro Study of ColisSn and Tobramycin Effectiveness against 
Gram(-) Bacteria obtained from Cystic Fibrosis Patients 
A. Bisiklis 1, M. Fot oulaki 9, P. Tsioutsias 1,St. Alexiou I)aniel 1, S. Nousia Arvanit akis 2 
iDepartment of Microbiolog3~ AHEPA University Hospital, School of Medicine, 
Thessaloniki, Greece; 2Fourth Pediatric Department, Aristotle University of 
Thessaloniki, Greece 
OBJECTIVE: The purpose of the present study was to determine tobramycin and 
col ist in effectiveness against Pseudomonas aeruginosa mad Achromobacter 
xylosoxidanas strains in vitro. 
MATERIALS AND METHODS:  Forty four Pseudomonas aeruginosa strains and 5 
Achromobacter xylosoxidas trains isolated from sputum cultures obtained from 
patients with cystic fibrosis were studied. The identification was performed by API 
20NE. The determination f effectiveness of colistin and tobramycin was performed 
by E test (AB BIODISK). Strains were considered resistant o tobramycin and 
colistin when the min imum inhibition concentrates (MICs) were >16pg/ml mad 
>32btg/ml, respectively. 
RESULTS: Pseudomonas aeruginosa strains revealed 75% sensitivity to t br amycin 
and 100% to colistin, respectively. One out of f ive Achromobacter xylosoxidans 
strains was sensitive to t obr amycin and colistin, another strain was resistant to both 
antibiotics. The remaining three strains were resistant to tobramycin and sensitive 
to colistin. 
CONCLUSIONS: a) A l l  Pseudomonas aeruginosa strains appeared sensitive to 
colistin and 75% were sensitive to t obr amycin.b) Achr omobacter xylosoxidans had 
decreased susceptibility to colislin. This is an interesting point as no patient in the 
present study was under treatment with colistin. 
206 
Evaluation of the Etest for the assessment of synergy of antibiotic 
combinations against multi-resistant Pseudomonas aeruginosa 
isolates fTom CysSc Fibrosis paSents 
B. Balke 1, M. Hogardt 2, S. Schmoldt 2, L. Hay ~, H. Weissbr odt 1, S. Hiius sler 4 
~Institut ffgr Medizinische Mikrobiologie und KrarKentu~ushygiene, Hanover; 
Germany, 2Max van Pettenkofer-Institut far Hygiene urul Medizinische 
Mikrobiologie, Munic, Germany, SInstitut far Biometrie, Hanover; Germany, 
4GeseIlschaf~ f gr Biotechnologische Forschung (GBF), Braunschweig, Germany 
The determination of synergistic effects of antimicrobial combinations can lead to 
improved therapeutic options in the antibiotic treatment of cystic fibrosis (CF) 
patients, who are chronically infected with multi~esis't ant Pseudomorw~s aeruginosa 
isolates. In this study we evaluated the performance of the Ell ipsometer test (Etest) 
in the assessment of synergy in comparison to the standard agar dilution 
checkerboard susceptibility test and determined the activity of two antimicrobial 
combinations against 163 multi  resistant/~ aeruginosa CF isolates. The agreement 
between the checkerboard and the Etest susceptibility test method was excellent 
(>90%) for both, non mucoid and mucoid CF strains. The highest rate of synergy 
was observed for the antibiotic ombination of ceft azidime and tobramycin (28.8% 
of the CF strains) as opposed to the antibiotic combination of meropenem and 
tobramycin (19.0%). However, the probability of synergy for the second antibiotic 
combination increased significantly when for the first antibiotic combination 
synergy had already been demonstrated (Fischer's exact est p 0.049). We conclude 
that the Etest is a valuable and practical method for routine microbiological 
dia~aostics improving the antibiotic options ha the treatment of CF patients 
chronically infected with/~ aeruginosa. 
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Patients with acute exacerbation of CF may improve on antibiotics yet have 
resistant Pseudomorw~s aeruginosa (PA) in sputum. This may be due to a synergistic 
effect of the antibiotic ombinations used to treat PA. Our aim was to test multiple 
isolates of PA from sputum taken before starting treatment, select hose resistant to 
both antibiotics and look at the predictive value of synergy testing on treatment 
outcome. 
Adults with CF, colonised with PA were treated for an exacerbation with two 
antibiotics for 14 days. Clinical response by days 7 mad 14 was measured by change 
in FEW 1 mad daily sputum weight, ha 9 exacerbations in 7 patients, one or more 
isolates of PA resistant to both prescribed antibiotics was found. The combinations 
used were tobramycin plus ceftazidime, aztreonam, meropenem or piperacil l in/ 
tazobactam. Antibiotic interactions were tested ha vitro using conventional synergy 
methods of checkerboard and t ime kil l  curves mad the recently described Mult ip le 
Combination Bactericidal Test. 
The results of synergy testing of the same isolate were different by the various 
methods.6 patients had more than one resistant isolate of PA in the same sputum 
with examples showing both indifference and synergy and a wide range of 
chequerboard synergy indices. No test reliably predicted the clinical outcome of 
treatment. This suggests that either the resistant isolates of PA were not the cause of 
the symptoms or that we lack a method of in vitro synergy testing that predicts the 
clinical effect of antibiotic ombination ha the treatment of infection with PA ha CF. 
